ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 632,71
0,00%
Dow Jones
40 211,72
0,53%
DAX
18 590,89
-0,95%
Brent Oil
83,84
-0,59%
Bitcoin
63 663,44
-1,83%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. RayzeBio Inc (RYZB)

  7. RayzeBio Inc (RYZB) Actualités

RYZB RayzeBio Inc

62,49
0,00 (0,00%)
15 Juil 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
RayzeBio Inc RYZB NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 62,49 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
62,49 62,49
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/3/202422:07EDGAR2Form 15-12G - Securities registration termination [Section..
27/2/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202415:20EDGAR2Form S-8 POS - Securities to be offered to employees in..
26/2/202415:20EDGAR2Form 8-K - Current report
23/2/202413:53EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
23/2/202412:59BWBristol Myers Squibb Announces Expiration of RayzeBio Tender..
14/2/202415:19EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
12/2/202414:54EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
12/2/202412:59BWBristol Myers Squibb and RayzeBio Announce Expiration of HSR..
07/2/202400:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202414:53EDGAR2Form SC 14D9 - Solicitation, recommendation statements
08/1/202416:06PRNUSKuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to..
27/12/202322:15EDGAR2Form SC14D9C - Written communication relating to third party..
26/12/202323:08EDGAR2Form SC14D9C - Written communication relating to third party..
26/12/202316:28DJNTrending: Bristol Myers Squibb to Buy RayzeBio
26/12/202314:35DJFRBristol Myers Squibb acquiert la société RayzeBio pour 4,1..
26/12/202314:32EDGAR2Form SC14D9C - Written communication relating to third party..
26/12/202314:26EDGAR2Form 8-K - Current report
26/12/202314:04DJNRayzeBio Shares Soar Premarket on Takeover by Bristol Myers
26/12/202313:46DJNBristol Myers Squibb to Buy RayzeBio for $4.1 Billion
26/12/202313:13GLOBEBristol Myers Squibb Adds Premier Radiopharmaceutical..
26/12/202312:59BW Bristol Myers Squibb Adds Premier Radiopharmaceutical..
18/11/202300:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202300:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:03EDGAR2Form 8-K - Current report
13/11/202322:01GLOBERayzeBio Reports Third Quarter 2023 Financial Results and..
06/11/202322:05GLOBERayzeBio to Participate in Upcoming Investor Conferences in..
01/11/202314:14EDGAR2Form 8-K - Current report
01/11/202311:00GLOBERayzeBio Appoints Industry Leader Tim Van Hauwermeiren to..
24/10/202314:00GLOBEFDA selects RayzeBio to Participate in the Inaugural CDRP..
18/10/202313:00GLOBERayzeBio to Present at European Society for Medical Oncology..
19/9/202322:01BWRayzeBio, Inc. Announces Closing of Upsized $358 Million..

Dernières Valeurs Consultées

NASDAQ
RYZB
RayzeBio
LSE
AZ43
Aberforth Split Level In...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés